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Abstract:  
The long-term relationship between 24-h ambulatory BP (ABP) and office BP in 
patients on therapy is not well documented. 
From a registry we included all patients in whom antihypertensive therapy needed to 
be up-titrated. Drug treatment included the direct renin inhibitor aliskiren or an ACE 
inhibitor (ACE-I)/angiotensin receptor blocker (ARB) or drugs not blocking the renin-
angiotensin-system (RAS), alone or on top of an existing drug regimen. In all patients 
office BP and 24-h ABP were obtained at baseline and after 1 year with validated 
devices. 
In the study population of 2722 patients there was a good correlation between the 
change in office BP and 24-hour ABP (systolic r=0.39, p<0.001; diastolic r=0.34, 
p<0.001). However the numeric decrease in office BP did not correspond to the 
decrease in ABP in a 1:1 fashion, e.g. a decrease of 10, 20 and 30 mmHg 
corresponded to a decrease of approximately 7.2, 10.5 and 13.9 mmHg in systolic 
ABP, respectively. The disproportionally greater decrease in systolic office BP 
compared to ABP was dependent on the level of the pretreatment BP, which was 
consistently higher for office than ambulatory BP. The white coat effect (difference 
between office BP and ABP) was on average 10/5 mmHg lower one year after 
intensifying treatment and the magnitude of that was also dependent on the 
pretreatment BP.  
There was a disproportionally greater decrease in systolic office BP than in ABP, 
which for both office and ABP seemed to depend on the pretreatment BP level. 
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Introduction  
In their most recent 2013 guidelines the European Society of Hypertension and the 
European Society of Cardiology1. have identified lower threshold values for 
diagnosing arterial hypertension with 24-hour ambulatory BP (ABP) (≥ 130/80 mmHg) 
than with office BP readings (≥140/90 mmHg). Since 2011 the National Institute for 
Health and Clinical Excellence Guidance (NICE) has recommended the use of ABP 
monitoring to confirm the diagnosis “arterial hypertension” if office BP was ≥ 140/90 
mmHg 2.In contrast, data on target BP based on 24-hour ABP to guide 
antihypertensive treatment are not provided in the guidelines1. The reason seems to 
be that no large scale, randomized clinical trial in patients on antihypertensive 
treatment has been conducted to analyze the effect of antihypertensive therapy on 
cardiovascular prognosis with 24-hour ABP as target BP.  
To develop a new consensus statement for ABP monitoring, most recently,  several 
critical analyses of the best available evidence from clinical and observational studies 
were carried out 3, 4. The results showed that the agreement between ABP and office 
BP is not simply a linear and that changes in ABP do not necessarily correspond to 
office BP in a 1:1 fashion. However, the long-term relationship between 24-h ABP 
and office BP in hypertensive patients on treatment and the change of BP due to 
therapeutic intervention remains ill documented.  
In the 3A Registry patients were prospectively followed for at least 1 year and had 
both office BP readings and 24-h ABP monitoring prior to and one year after 
intensifying antihypertensive medication to achieve target systolic office BP < 140 
mmHg 5, 6. This database represents therefore a tool allowing us to compare the 
changes of office BP measurements to the changes of ABP obtained under real life 
conditions. 
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Methods 
3A Registry 
The present analysis is based on the data of the 3A Registry6. The Registry is a 
prospective, observational, non-interventional, multi-centre registry listed under 
clinicaltrials.gov, NCT01454583 and the VfA database, a resource for non-
interventional studies (http://www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-
arzneimitteln/nisdb/nis-details/_616). Details of the study design and baseline data 
have been published in more detail elsewhere.5 
In brief, consecutive patients with known or newly diagnosed arterial hypertension in 
whom the physician had decided independently and per best clinical judgment to 
initiate or intensify antihypertensive therapy were eligible for inclusion. The only 
exclusion criteria were participation in a randomised controlled clinical trial and 
foreseeable problems to perform follow-up visits. Depending on the initiated 
medication, patients were part of one of the three following study groups: 
- 1. Treatment with the direct renin inhibitor aliskiren or 
- 2. An ACE inhibitor (ACE-I) or angiotensin receptor blocker (ARB) or  
- 3. Drugs not blocking the renin-angiotensin-system (Non-RAS). 
Reflecting the utilised medication of the three study groups, the registry was called 
3A: Aliskiren, ARB/ACE-I and others (in German called “Andere, i.e. others”). 
Medication was given alone or on top of an existing drug regimen.  
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The data were collected in web-based format with a standardised questionnaire 
(electronic case report form, eCRF). Measures of quality control included automated 
plausibility checks during data entry, queries after data entry, and in 10 % of the 
patients, on-site monitoring with source data verification. All data, if available, were 
collected during the clinical examination or from the review of the patient chart. Data 
were recorded at inclusion (baseline) and during follow-up visits. 
Patients 
In 6139 patients 24-hour ABP monitoring (ABPM) was performed at baseline visit. At 
the 1 year examination, in 2722 hypertensive patients 24-hour ABPM was repeated 
in parallel to office BP measurements. Office BP was assessed with the standard 
devices (all were oscillometric devices) available at the physicians’ office (manual 
sphygmomanometers or semi-automated devices), which according to German 
legislation must have a calibration validation. Furthermore, the German guidance for 
measuring office BP (sitting position, after 5 minutes of rest, at least 2 repeated 
measurements) had to be followed. 24-hour ABPM was also only performed with 
validated devices (see German guidelines: 
http://www.hochdruckliga.de/blutdruckmessgeraete-mit-pruefsiegel.html), routinely 
used in the respective office. Average of office BP readings and means of 24-hour 
ABP (minimum requirements ≥ 50 measurements during at least a ≥ 22 hour period), 
day-time ABP and night-time ABP were entered into the database. 
Since at the time of inclusion patients had uncontrolled hypertension and the 
physician had decided to initiate or intensify antihypertensive therapy, we have 
specified the 1 year follow-up examination for our analyses when a stable situation 
was achieved.  
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Statistical methods 
Continuous variables were summarized with descriptive statistics (absolute numbers, 
means, standard deviation, or medians with 25. and 75. percentile as appropriate). 
Categorical data were described by the number and percentage of subjects in each 
category. As univariate test of location we applied the signed rank test. Statistical 
comparisons between groups were performed by Pearson’s chi square for 
categorical variables, or Kruskal-Wallis test for continuous measures. Percentages 
were calculated on the basis of patients with data for each respective parameter. All 
variables showed moderate deviations from a normal distribution, as evidenced by 
the Kolmogorow-Smirnow-Test.  
Like other biological measures, changes in both ABP and office BP may depend on 
baseline BP levels (Wilder Law) 7. Previous analyses comparing office BP versus 
ABP applied a linear regression model simple statistical models8. It remains to be 
determined whether the relationship between office and ABP can be described by 
simple, proportional or linear formulas, since BP (which should not fluctuate 
according to the assumptions of the statistical model) is in fact a highly variable 
biological parameter. Thus, the statistical premises to run simple regression models 
are not entirely fulfilled, though widely used9, 10. Evaluating ABP and office BP by 
means of univariate or bivariate models hence runs the risk of inadequately 
simplifying a complex reality. We therfore further developed and applied a 
multivariate (“four-variate”) model of BP change. [Details see annex 1]. 
We conducted all analyses with SAS 9.3 (SAS Institute, Inc., Cary, NC, USA). P-
values ≤0.05 (two-sided) were considered to be significant. 
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Results 
Patients´ characteristics 
In a total of 2722 patients office BP and 24-h ABP were obtained both at baseline 
and after 1 year. Clinical characteristics of the study population were: mean age 64, 
mean BMI 28.4 kg/m², 45 % women, mean hypertension duration 6.9 years, average 
regimen 3 antihypertensive medications. Of the 2722 patients 85 % had 
hyperlipidemia, 14 % were current smokers, 30 % had diabetes, 31 % cardiovascular 
diseases and 9 % chronic kidney diseases (Table 1).  
 
Decrease in Office versus Ambulatory BP 
In the whole study population both office BP and 24-h ABP decreased after one year 
of treatment. Office BP decreased by 18.7±20/9.6±12 mmHg, i.e. from 
156.2±18/90.6±11 mmHg at baseline to 137.5±14/81.0±8 mmHg at one year. In 
parallel, 24-h ABP decreased by 10.1±15/6.1±10 mmHg, from 146.2±15/85.5±11 
mmHg at baseline to 136.2±13/79.4±8 mmHg after one year. Daytime and nighttime 
ABP decreased accordingly (daytime from 151±16 / 88±11 to 140±13 / 82±9 mmHg; 
nighttime from 136±17 / 79±12 to 126±15 / 73±9 mmHg). The change in office BP 
and 24-hour ABP correlated highly significant with each other (systolic r=0.39, 
p<0.001; diastolic r=0.34, p<0.001) (figure 1). Similar correlations were observed for 
daytime (figure S3A and S3B) and nighttime ABP (figure S3C and S3D). However, 
the numeric decrease in office BP did not correspond to the decrease in ABP in a 1:1 
fashion, neither for 24-h-ABP nor for daytime and nighttime ABP. For any given fall of 
office BP, the fall in ABP was clearly less than the one in office BP. 
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By applying a linear regression model, for any given pretreatment office BP (including 
156/91 mmHg reflecting the average value of our population), a decrease of 10, 20 
and 30 mmHg in systolic office BP corresponded to a decrease of 7.1, 10.5 and 13.9 
mmHg in systolic ABP, respectively (figure 2). By applying the non-linear, multivariate 
additive mixed model (given for the average BP 156/91 mmHg) decreases of 10, 20 
and 30 mmHg in systolic office BP corresponded to significantly smaller decreases in 
systolic ABP of 7.2, 10.6, and 14.0 mmHg respectively (figure 2A). Similar findings 
were obtained for changes in diastolic BP (figure 2B). When the analysis was 
repeated for daytime and nighttime ABP, a similar striking difference between the 
change in office versus daytime and nighttime ABP was observed (figure S4A-D). 
Direct comparison of the two models showed that the non-linear multivariate additive 
mixed model yielded even greater differences between office and ABP values than 
the linear regression model, in particular in the higher range of pretreatment office BP 
(see Annex 1, figure S1 and S2).  
 
BP decrease and pre-treatment BP level 
When the actually measured pretreatment office BP were stratified into 10 mmHg 
groups (excluding those with systolic < 140 mmHg and diastolic < 90 mmHg, 
respectively), the measured decrease in both office and 24 hour ABP ( in absolute 
terms and in percent) were highly dependent on the pretreatment BP (table 2A and 
B). For example, with a pretreatment systolic office BP in the range of 140 to 149 
mmHg, the decrease in office and ambulatory BP were -11.3 mmHg (or -7.6 %) and -
8.9 mmHg (or -5.7%), respectively (figure 3A). In contrast, with pretreatment systolic 
office BP ≥180 mmHg, the decrease in office and ambulatory BP was -51.4 mmHg 
(or -26 %) as opposed to a decrease in ABP by -18.5 mmHg (or -11 %). Hence, the 
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disproportional decreases in systolic office BP compared to ABP were dependent on 
the pretreatment systolic BP (see table 2, irrespective whether changes are given in 
absolute or percent terms. A similar result was found for the relation of changes in 
diastolic office versus ABP (figure 2B and table 2B).  
The analysis for daytime and nighttime ABP displayed similar results (table S1A-D). 
For example with a pretreatment systolic office BP in the range of 160 to 169 mmHg, 
the decrease in office and daytime ambulatory BP were -23.6 mmHg (or -14.6 %) and 
-13.3 mmHg (or –8.1 %), respectively (figure S4A and S4B).  
 
White coat effect and pretreatment BP level 
The white coat effect defined as difference between office and 24-h ABP decreased 
after 1 year by 8.6 ± 20 / 3.5 ± 12 mmHg (baseline: 10±18 / 5.1±11, follow-up 1.3±13 
/ 1.6±8.7 mmHg, p<0.001). Likewise, when defined as difference between office and 
day time ABP, the white coat effect declined by 7.5±20.3 / 3.2±13 mmHg after 1 year. 
Interestingly, the decrease of white coat effect after 1 year was dependent on the 
pretreatment BP (figure 4). Thus, the observed decrease of the white coat effect 
contributed to the disparate changes in office BP and ABP after 1 year. 
 
Discussion 
 
Several important findings evolve from the present study. First we showed that 
changes in BP after initiating or up-titrating antihypertensive medication are 
dependent on the pre-treatment BP values. This was found to be true for both office 
and ABP. This phenomenon that the pre-treatment level determines to a large extent 
HYPE201403140-T R2 
14369_finaldraft.docx 11 
the change per se is not restricted to change in BP only but has also been observed 
for changes in heart rate11, or LDL cholesterol12. The law of initial value (German: 
Ausgangswertgesetz) was first described by Josef Wilder in 1927 (published in 1932) 
who proposed that the “direction of response of body function to any agent depends 
to a large degree on the initial value of that function” 7. However, even today it 
remains uncertain whether the Wilder’s law of initial value represents a real biological 
phenomenon or simply a statistical artifact.  
 
From a clinical perspective, the Wilder’s law of initial value is an important concept, 
since it predicts that in the most severe hypertensive patients the fall in BP will be 
greater with the same medication than in those with less severe hypertension. If the 
effect were similar (i.e. the fall in BP were independent of pre-treatment level), we 
would encounter many more clinical complications related to hypotension with 
antihypertensive treatment. Wilder’s law of initial value thus indicates that we have to 
take the pretreatment level into account when comparing the efficacy of various 
antihypertensive medications in clinical trials.  
 
Our second finding is, that change in office and ABP are not related to each other in a 
1:1 fashion. When the decreases of systolic 24-hour daytime/nighttime ABP were 
plotted against the decrease of systolic office BP, the regression lines were not the 
line of identity. This observation again has important implications. Based on the 
average value of the pretreatment systolic BP of our population (156 mmHg), we 
calculated, that decreases of 10, 20 and 30 mmHg in the office systolic BP 
corresponded to decreases of 7.1, 10.5 and 13.9 mmHg in systolic ABP (figure 2A). 
The ratio between these two changes is obviously not constant; it depends on the fall 
in office and ABP respectively. Similar observations were also made comparing 
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changes in daytime and nighttime ABP with office BP changes (Figure 1 and 2). 
Likewise, analyzing diastolic instead of systolic BP, consistent findings were observed 
through with numerically lower magnitude. By using a similar approach, Mancia and 
colleagues documented in a meta-analysis that a fall of 10 mmHg in office systolic 
BP corresponded to a fall in 24-hour systolic BP to nearly the same extent, whereas 
a fall of 30 mmHg in office systolic BP corresponded to a fall of about 20 mmHg in 
ABP only 4. However, a direct comparison of the 2 studies is not possible, since the 
basis of the analysis and pretreatment BP differed substantially between (based on 
mean BP of study cohorts) Mancia’s metaanalysis and our large patient-based 
analysis. 
 
Our third finding is that the white coat effect in patients on antihypertensive therapy 
decreases over time by approximately 10/5 mmHg on average, but was still present 
after one year. Such a decrease of the white coat effect over 1 year appeared to be 
dependent on pretreatment BP as well (figure 4), being neglible if pretreatment BP is 
close to target BP < 140/90 mmHg, but substantial with severely elevated BP values. 
This result is reflected by the “volatile BP component” (fig S1A and S1B dark grey 
column) that decreases after 1 year (fig S1A and S1B dark orange column) to a large 
extent if pretreatment BP is high. Thus, the greater fall in office BP in patients with 
severely elevated pretreatment BP is caused to large extent by the reduction of the 
white coat effect. Since 24-hour ABP is void of white coat and placebo effect, the 
changes in ABP are smaller and the pretreatment BP level lower 13-15, thereby 
explaining at least in part why changes in office and ABP are not related to each 
other in a 1:1 fashion. The statistical phenomenon regression to mean might be also 
one contributing factor, but it is impossible to quantify the effect size from our data 
set.  
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When analyzing clinical studies with the primary objective of assessing BP changes, 
our findings have significant implication for their interpretation. The average systolic 
pre-treatment BP in the 3A Registry population was 156 mmHg and a decrease of 
office systolic BP of approximately 20 mmHg was observed. If we assume that the 
pre-treatment ABP were also 156 mmHg (in fact it was 146 mmHg), we would 
according to the Wilder’s law of initial value expect a greater fall in ABP than the 
actually observed fall in ABP of 10 mmHg only. 
 
The Symplicity-HTN 2 study illustrates the importance of our findings. Systolic BP 
dropped by 32/12 mmHg by office BP with pretreatment BP of 178/96 mmHg, 
whereas the changes in ambulatory systolic BP were 11/7 mmHg observed from a 
pretreatment level of 146/86 mmHg16. Similar observations were made in our 3A 
Registry. BP in 274 patients whose pre-treatment systolic office BP was between 170 
and 179 mmHg decreased by 31 mmHg in office values but “only” 13 mmHg in ABP 
values.  
 
Our study was not a randomized controlled clinical trial but the one of a non-
interventional observation study which may be considered as a limitation. Both 
designs have their strength and weakness discussed otherwise in detail 5. The use of 
different methods and devices for BP measurements may have created a greater 
variability of the results but the same device was used at baseline and after 1 year, 
and all devices were validated according to German legislation following the 
recommendations and validation according to the German Hypertension Society. 
Furthermore, time of office BP measurements and the peak levels of multiple drugs 
taken by the patients were not assessed due to the obvious inherent difficulties of 
HYPE201403140-T R2 
14369_finaldraft.docx 14 
such an effort in a large-scale trial. The white coat effect was determined by the 
difference of office minus 24-hour or daytime ambulatory blood pressure, which 
represents and indirect approach of the white coat effect since the ambulatory BP 
measurement depend also on other factors (e.g. level of activities), which are 
inherent to the ambulatory BP measurements. 
 
Perspective 
Both, changes in office BP and ABP are dependent on the pre-treatment BP level. 
Since the pre-treatment BP of ABP is usually lower, decreases in ABP are therefore 
smaller than those observed with office BP. A simple recipe to overcome these 
limitations in interpretation of changes in ABP is unfortunately not available due to the 
complexity of the phenomenon. Thus, changes in ambulatory BP in clinical studies as 
well as in individual patients need careful judgment and analysis bearing in mind 
Wilder’s law of the initial value. 
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Novelty and Significance  
 
What Is New! 
• We found a strong dependency of treatment induced changes in BP from 
pretreatment levels.  
 
What Is Relevant?  
• At any given pretreatment BP we observed a disproportionally greater 
decrease in systolic office BP compared to ambulatory BP.   
• The white coat effect was on average 10/5 mmHg lower one year after 
intensifying treatment and also dependent on pre-treatment BP.   
 
Summary 
In this study cohort of 2722 patients changes in office BP were not related to changes 
in ambulatory BP in a 1:1 fashion. Our results should be taken into account when 
judging decrease in BP in individual patients and clinical studies.  
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Figure Legend: 
 
Figure 1A:  Correlation of the decrease in systolic office BP and the 24-h ABP (all 
patients). The regression line (y=4.5+0,30 x, where x denotes change in 
office BP and y change in ABP 24 means after 1 year) and its 95%CI are 
illustrated 
 
Figure 1B: Correlation of the decrease in diastolic office BP and the 24-h ABP (all 
patients). The regression line (y=3.4 + 0.28 x, where x denotes change in 
office BP and y change in ABP 24 means after 1 year) and its 95%CI are 
illustrated 
 
Figure 2A:  BP decreases in 24-h-systolic office BP and corresponding changes in 
systolic ABP. BP changes have been (calculated according to the two 
different statistical approaches from the average pretreatment BP of our 
patients [156/91 mmHg]) and are given for 3 different scenarios: change 
in office BP -10 mmHg (A), -20 mmHg (B) and -30 mmHg (C). (ABPM 
24h means (predicted by linear regr.) und ABPM 24h means (predicted 
by mixed model). 
 
Figure 2B: BP decreases in 24-h-diastolic office BP and corresponding changes in 
diastolic ABP. BP changes have been (calculated according to the two 
different statistical approaches from the average pretreatment BP of our 
patients [156/91 mmHg]) and are given for 3 different scenarios: change 
in office BP -10 mmHg (A), -20 mmHg (B) and -30 mmHg (C). (ABPM 
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24h means (predicted by linear regr.) und ABPM 24h means (predicted 
by mixed model). 
 
Figure 3: Decreases of office and ambulatory systolic 24-h-BP (measured values) 
categorized by pretreatment office systolic BP. (Change in office systolic 
BP; Change in mean of 24-h ambulatory systolic BP). 
 
Figure 4A: Decrease of systolic white coat effect (office BP minus 24-h ABP (yellow) 
and office BP minus daytime BP in green) categorized by pretreatment 
office BP.  
Figure 4B: Decrease of diastolic white coat effect (office BP minus 24-h ABP 
(yellow) and office BP minus daytime BP in green) categorized by 
pretreatment office BP.  
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Table1: Heterogeneity of study population 
Clinical parameter Patients with ABPM at 1 year visit 
(N=2722) 
age (years) (mean, quartile) 63.7 (55-71) 
female sex, % (n/N) 45 (1233/2739) 
Height, cm (mean, quartile) 170 (165-177) 
Weight, kg (mean, quartile) 84 (75-94) 
BMI, kg/m² (mean, quartile) 28.4 (25.9-31.5) 
  
Data about hypertension at baseline, 
% (n/N) 
 
- Recently diagnosed hypertension 12.4 (340/2739) 
- Known hypertension 87.6 (2399/2739) 
- duration of hypertension, years 
(mean quartile) 
6.9 (2.7-12.4) 
- group with aliskiren-based 
treatment 
69.6 (1907/2739) 
- group with ACE-I/ARB-based 
treatment 
18.1 (496/2739) 
- group with Non-RAS-based 
treatment 
12.3 (336/2739) 
- mean count of antihypertensive 
drugs 
3.0 
  
BP data at baseline / 1 year, mm Hg  
(mean ± SD) 
baseline 1 year 
-  systolic office BP  157 ± 17.9 137.5 ± 14.0 
-  diastolic office BP  91 ± 10.9 81.1 ± 8.2 
-  systolic ABP (24-hours)  146 ± 14.8 136.2 ± 12.7 
-  diastolic ABP (24-hours)  86 ± 10.6 79.4 ± 8.5 
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-  systolic day-time ABP  151 ± 15.5 139.5 ± 12.5 
-  diastolic day-time ABP  88 ± 11.1 81.8 ± 8.7 
-  systolic night-time ABP  136 ± 16.9 126.4 ± 14.5 
-  diastolic night-time ABP  79 ± 11.5 72.6 ± 9.0 
 
ABP, ambulatory blood pressure; BMI, Body mass index; BP blood pressure. 
Quantitative values are expressed as mean and (SD) and median and 
(interquartiles), respectively; Qualitative variables are expressed as percentages and 
numbers (n/N) 
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Table 2A: Decrease of systolic office and 24-h-ambulatory BP (measured values) 
categorized by pretreatment systolic office BP 
BP 
decrement by 
pretreatment 
systolic office 
BP 
Change in Office 
BP [mmHg] 
Change in ABP 
24h means 
[mmHg] 
Change in Office 
BP [%] 
Change in ABP 
24h means [%] 
n Mean±Std. n Mean±Std. n Mean±Std. n Mean±Std. 
Systolic blood 
pressure 
[mmHg] 
(baseline) 
499 7.8±12.9 501 7.0±11.8 499 5.4±9.0 501 4.7±8.3 140-149 
150-159 663 14.5±13.4 667 9.5±13.7 663 9.5±8.8 667 6.1±9.2 
160-169 609 23.6±13.4 611 11.9±14.5 609 14.6±8.3 611 7.5±9.3 
170-179 274 31.0±15.0 276 12.8±15.8 274 18.0±8.7 276 7.8±10.1 
≥ 180 323 46.3±19.3 329 16.6±19.4 323 24.2±9.3 329 9.7±12.1 
All 2368 21.7±18.9 2384 10.9±15.0 2368 12.9±10.6 2384 6.9±9.7 
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Table 2B: Decrease of diastolic office and 24-h-ambulatory BP (measured values) 
categorized by pretreatment diastolic office BP 
BP decrement 
by 
pretreatment 
diastolic office 
BP 
Change in Office 
BP [mmHg] 
Change in ABP 
24h means 
[mmHg] 
Change in Office 
BP [%] 
Change in ABP 
24h means [%] 
n Mean±Std. n Mean±Std. n Mean±Std. n Mean±Std. 
Diastolic blood 
pressure 
[mmHg] 
(baseline) 
807 2.9±7.8 808 3.9±8.8 807 3.5±9.5 808 4.2±10.6 80-89 
90-99 962 11.1±8.6 969 6.4±9.6 962 11.9±9.2 969 6.7±11.1 
100-109 580 17.8±7.8 586 8.6±9.2 580 17.5±7.6 586 8.8±10.0 
110-119 86 25.4±8.6 88 10.8±11.0 86 22.8±7.5 88 10.2±13.2 
≥ 120 47 37.9±12.1 47 13.0±14.2 47 30.8±9.3 47 12.0±13.2 
All 2482 11.0±11.0 2498 6.4±9.6 2482 11.2±10.9 2498 6.6±11.0 
 
Please note that some patients had systolic and diastolic office BP below 140 and 80 
mmHg, respectively, that explain the different total numbers of patients listed in table 2A 
and 2B.  
 
 
 
Figure 1A 
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Online Supplemental Material  
 
Description of statistical models to predict changes in ABP by office BP readings 
To overcome shortcoming of the classic linear regression model, we modelled the 
relation between baseline and follow-up of both ABP and office BP by a nonlinear, 
additive, mixed model. This model has advantages compared to simple models - like 
linear regression models or relative BP (i.e. percent) reductions - when assessing 
reductions of baseline values in heterogeneous patient groups. In the 3A study 
patients with and without cardiovascular disease, diabetes, severe hypertension, and 
chronic renal failure were included thereby reflecting a clinically heterogenous 
population of hypertensive patients. Indeed, baseline values were very 
heterogeneous, as baseline ABP and office BP differed substantially between the 
various subgroups of patients.  
 
We integrated four BP variables in this statistical approach and thus set up a 
multivariate model with four dependent variables: baseline and follow-up office BP, 
as well as baseline and follow-up 24-h ABP averages. Their mutual dependencies 
can be represented by several common and correlating BP components: 
 
- A more in the long-term upregulated pressure (which at the end leads to the 
diagnosis: “hypertension”) that adds to a normal value of ABP and office BP 
and which is usually reduced by therapy (from now on called “static pressure”),  
- an additional highly “fluctuating” excess pressure (which corresponds in part to 
the white coat phenomenon), adding only to office BP and usually being 
reduced by therapy, too (from now on called “volatile pressure”), 
- individual deviations (in each patient) above and below the static pressure at 
baseline and follow-up, which correlates between ABP mean and office BP 
(corresponding to the patient’s stage or severity of hypertension), 
- individual short-term deviations above and below the volatile excess values, at 
baseline and follow-up, contributing only to office BP (corresponding to the 
individual patient’s arousal reaction).  
-  
By estimating separate reduction coefficients for static and volatile components, we 
were able to split reduction of office BP into a common part adding to the reduction of 
ABP and a more specific part belonging to office BP changes only. Figure S1A and 
S1B illustrates the various BP components: the common additive part and specific 
BP components by different shades of the colors, accordingly. 
As a by-product, we obtained an estimated formula for reduction of 24h ABP means 
when knowing only baseline and follow-up values of office BP. 
 
For systolic BP (mmHg) after 1y: Y ≈ 0.280 × X1 − 0.334 × X2 + 12.3 
For diastolic BP (mmHg) after 1y: Y ≈ 0.297 × X1 − 0.238 × X2 − 1.7 
where Y denotes ABP reduction after 1 year, X1 office BP at baseline and X2 office 
BP at follow-up.  
 
We estimated all model parameters by fitting a nonlinear, multivariate, additive mixed 
model. In technical terms, we applied SAS procedure “nlmixed”, maximizing the 
likelihood by a quasi-Newton algorithm and integrating over the random effects via 
adaptive Gauss-Hermite quadrature. Only patient records with all four variables 
(baseline and follow-up values for both ABP and office BP) observed entered 
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computations. Confidence limits for all estimates are approximate and refer to a 
confidence level of 95%.  
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Tables: 
 
Table S1A: Decrease of systolic office and daytime ambulatory BP (measured values) categorized by pretreatment systolic office BP 
 
BP decrement by pretreatment 
systolic office BP 
Change in Office BP 
[mmHg] 
Change in ABP daytime 
means [mmHg] 
Change in Office BP 
[%] 
Change in ABP daytime 
means [%] 
n Mean±Std. n Mean±Std. n Mean±Std. n Mean±Std. 
Systolic blood pressure [mmHg] 
(baseline) 
499 7.8±12.9 477 7.3±12.7 499 5.4±9.0 477 4.7±8.6 140-149 
150-159 663 14.5±13.4 631 11.1±14.5 663 9.5±8.8 631 6.9±9.6 
160-169 609 23.6±13.4 582 13.3±15.9 609 14.6±8.3 582 8.1±9.8 
170-179 274 31.0±15.0 267 15.5±17.9 274 18.0±8.7 267 9.0±11.0 
≥ 180 323 46.3±19.3 318 16.2±20.2 323 24.2±9.3 318 9.2±12.2 
All 2368 21.7±18.9 2275 12.1±16.1 2368 12.9±10.6 2275 7.3±10.2 
 
Table S1B: Decrease of diastolic office and daytime ambulatory BP (measured values) categorized by pretreatment diastolic office BP 
BP decrement by pretreatment 
diastolic office BP 
Change in Office BP 
[mmHg] 
Change in ABP daytime 
means [mmHg] 
Change in Office BP 
[%] 
Change in ABP daytime 
means [%] 
n Mean±Std. n Mean±Std. n Mean±Std. n Mean±Std. 
Diastolic blood pressure 
[mmHg] (baseline) 
807 2.9±7.8 763 4.1±8.9 807 3.5±9.5 763 4.3±10.5 80-89 
90-99 962 11.1±8.6 921 6.2±10.5 962 11.9±9.2 921 6.2±11.8 
100-109 580 17.8±7.8 567 9.9±10.5 580 17.5±7.6 567 9.7±11.0 
110-119 86 25.4±8.6 84 12.1±12.8 86 22.8±7.5 84 10.9±14.0 
≥ 120 47 37.9±12.1 43 14.0±17.3 47 30.8±9.3 43 12.2±15.0 
All 2482 11.0±11.0 2378 6.8±10.6 2482 11.2±10.9 2378 6.7±11.6 
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Table S1C: Decrease of systolic office and nighttime ambulatory BP (measured values) categorized by pretreatment systolic office BP 
BP decrement by pretreatment 
systolic office BP 
Change in Office BP 
[mmHg] 
Change in ABP nighttime 
means [mmHg] 
Change in Office BP 
[%] 
Change in ABP nighttime 
means [%] 
n Mean±Std. n Mean±Std. n Mean±Std. n Mean±Std. 
Systolic blood pressure 
[mmHg] (baseline) 
499 7.8±12.9 468 6.9±13.8 499 5.4±9.0 468 4.7±10.5 140-149 
150-159 663 14.5±13.4 620 8.9±15.4 663 9.5±8.8 620 5.9±11.4 
160-169 609 23.6±13.4 562 11.0±15.3 609 14.6±8.3 562 7.3±10.6 
170-179 274 31.0±15.0 266 13.5±18.2 274 18.0±8.7 266 8.5±12.1 
≥ 180 323 46.3±19.3 311 14.5±19.6 323 24.2±9.3 311 9.1±13.4 
All 2368 21.7±18.9 2227 10.3±16.3 2368 12.9±10.6 2227 6.8±11.5 
 
Table S1D: Decrease of diastolic office and nighttime ambulatory BP (measured values) categorized by pretreatment diastolic office 
BP 
BP decrement by pretreatment 
diastolic office BP 
Change in Office BP 
[mmHg] 
Change in ABP nighttime 
means [mmHg] 
Change in Office BP 
[%] 
Change in ABP nighttime 
means [%] 
n Mean±Std. n Mean±Std. n Mean±Std. n Mean±Std. 
Diastolic blood pressure 
[mmHg] (baseline) 
807 2.9±7.8 752 3.5±9.1 807 3.5±9.5 752 3.9±12.2 80-89 
90-99 962 11.1±8.6 896 6.2±11.1 962 11.9±9.2 896 6.7±13.9 
100-109 580 17.8±7.8 557 8.6±10.6 580 17.5±7.6 557 9.3±12.4 
110-119 86 25.4±8.6 82 9.1±12.8 86 22.8±7.5 82 8.7±16.8 
≥ 120 47 37.9±12.1 43 15.3±15.6 47 30.8±9.3 43 15.0±15.6 
All 2482 11.0±11.0 2330 6.2±10.8 2482 11.2±10.9 2330 6.6±13.4 
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Figure S1A: 
 
Dependency of systolic BP reduction effects of static and volatile BP components 
from pretreatment BP (upper part). Grey columns indicate pretreatment BP and 
orange columns BP after 1 year.  
 
Figure S1B: 
 
 
Dependency of diastolic BP reduction effects between static and volatile BP 
components from pretreatment BP (lower part). Grey columns indicate pretreatment 
BP and orange columns BP after 1 year.  
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Figure S2A: Systolic BP 
 
Comparison of the differences between decreases in systolic office BP minus 
predicted decreases in systolic ABP for various pretreatment BP derived from both 
the linear regression model (blue bars) versus the values derived from the non-linear 
multivariate additive mixed model (red bars). 
 
Figure S2B: Diastolic BP 
 
Comparison of the differences between decreases in diastolic office BP minus 
predicted decreases in diastolic ABP for various pretreatment BP derived from both 
the linear regression model (blue bars) versus the values derived from the non-linear 
multivariate additive mixed model (red bars). 
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Figure S3A: Decrease of the systolic office BP and daytime ABPM (all patients) 
 
Correlation of the decrease in systolic office BP and daytime ABP (all patients). The 
regression line (y=5.5 + 0.30 x, where x denotes change in office BP and y change in 
daytime ABP means after 1 year) and its 95%CI are illustrated. 
 
Figure S3B: Decrease of the diastolic office BP and daytime ABPM (all patients) 
  
  
Correlation of the decrease in diastolic office BP and daytime ABP (all patients). The 
regression line (y=3.6 + 0.29 x, where x denotes change in office BP and y change in 
daytime ABP means after 1 year) and its 95%CI are illustrated.  
D
ec
re
as
e 
of
 s
ys
t. 
A
B
P
M
 d
ay
tim
e 
m
ea
ns
 [m
m
H
g]
-60
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
70
80
90
Decrease of systolic office BP [mmHg]
-80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100 110
D
ec
re
as
e 
of
 d
ia
st
. A
B
P
M
 d
ay
tim
e 
m
ea
ns
 [m
m
H
g]
-60
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
70
80
Decrease of diastolic office BP [mmHg]
-50 -40 -30 -20 -10 0 10 20 30 40 50 60 70
HYPE201403140-T3 
14369_Suppl_TextFiguresTables.docx 9 
Figure S3C: Decrease of the systolic office BP and nighttime ABPM (all patients) 
 
Correlation of the decrease in systolic office BP and nighttime ABP (all patients). The 
regression line (y=4.7 + 0.26 x, where x denotes change in office BP and y change in 
nighttime ABP means after 1 year) and its 95%CI are illustrated. 
 
Figure S3D: Decrease of the diastolic office BP and nighttime ABPM (all patients) 
 
Correlation of the decrease in diastolic office BP and nighttime ABP (all patients). 
The regression line (y=3.3 + 0.26 x, where x denotes change in office BP and y 
change in nighttime ABP means after 1 year) and its 95%CI are illustrated. 
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Figure S4A:  BP decreases in systolic office BP and corresponding changes in daytime 
systolic ABP.  
 
BP decreases in systolic office BP and corresponding changes in daytime systolic ABP. 
BP changes have been (calculated according to the two different statistical approaches 
from the average pretreatment BP of our patients [156/91 mmHg]) and are given for 3 
different scenarios: change in office BP -10 mmHg, -20 mmHg and -30 mmHg. (daytime 
ABPM means (predicted by linear regr.) and ABPM 24h means (predicted by mixed 
model). 
 
  
8.2
9.210.0
11.6 12.4
20.0
14.9 15.6
30.0
Reduction of:
Office BP
ABPM daytime means, linear regr.
ABPM daytime means, mixed model
P
re
di
ct
ed
 re
du
ct
io
n 
of
 s
ys
to
lic
 B
P
 [m
m
H
g]
 0
 5
10
15
20
25
30
10 20
Given reduction of systolic office BP [mmHg]
30
HYPE201403140-T3 
14369_Suppl_TextFiguresTables.docx 
Figure S4B: BP decreases in diastolic office BP and corresponding changes in daytime 
diastolic ABP.  
 
BP decreases in diastolic office BP and corresponding changes in daytime diastolic 
ABP. BP changes have been (calculated according to the two different statistical 
approaches from the average pretreatment BP of our patients [156/91 mmHg]) and are 
given for 3 different scenarios: change in office BP -10 mmHg, -20 mmHg and -30 
mmHg. (daytime ABPM means (predicted by linear regr.) and ABPM 24h means 
(predicted by mixed model). 
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Figure S4C:  BP decreases in systolic office BP and corresponding changes in nighttime 
systolic ABP.  
 
BP decreases in systolic office BP and corresponding changes in nighttime systolic 
ABP. BP changes have been (calculated according to the two different statistical 
approaches from the average pretreatment BP of our patients [156/91 mmHg]) and are 
given for 3 different scenarios: change in office BP -10 mmHg, -20 mmHg and -30 
mmHg. (nighttime ABPM means (predicted by linear regr.) and ABPM 24h means 
(predicted by mixed model). 
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Figure S4D: BP decreases in diastolic office BP and corresponding changes in 
nighttime diastolic ABP.  
 
BP decreases in diastolic office BP and corresponding changes in nighttime diastolic 
ABP. BP changes have been (calculated according to the two different statistical 
approaches from the average pretreatment BP of our patients [156/91 mmHg]) and are 
given for 3 different scenarios: change in office BP -10 mmHg, -20 mmHg and -30 
mmHg (nighttime ABPM means (predicted by linear regr.) and ABPM 24h means 
(predicted by mixed model). 
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